Metabolic Dysfunction–Associated Steatotic Liver Disease and Glucagon-like Peptide-1 Drugs: What Patients Want to Know
Nov
2026
Description
Glucagon-like peptide-1 (GLP-1) drugs—including both GLP-1 receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide [GIP] receptor agonists—have become ubiquitous in the public arena. These drugs represent some of the most promising treatment options for persons with metabolic dysfunction–associated steatohepatitis (MASH) because they treat the underlying comorbidities (obesity and diabetes) as well as MASH. Additionally, they have proven cardiovascular benefits. Persons with MASH want reliable information on whether they are eligible to be treated with GLP-1 drugs; what to expect in terms of response; how to monitor response; and how to manage potential side effects.
Key topics addressed by speakers include:
Why GLP-1 drugs are showing such promise in metabolic dysfunction–associated steatotic liver disease (MASLD)
Mechanism of liver benefit
Expected treatment response and variability
Tolerability and side effect management
Eligibility, nonresponse, and discontinuation
Presentations
2:00 PM
- 2:20 PM
Convention Center - Mile High Ballroom 4DEF
Why Are Current and Pipeline GLP-1/GIP Therapies So Promising in Metabolic Dysfunction–Associated Steatotic Liver Disease Across the Disease Spectrum and How Do You Select and Counsel Patients for Treatment?
Rohit Loomba, MD, MHSc, FAASLD | Presenter
2:20 PM
- 2:40 PM
Convention Center - Mile High Ballroom 4DEF
Patient Experiences of Treatment With Glucagon-like Peptide-1 Drugs for Metabolic Dysfunction–Associated Steatohepatitis
Kerry M. Sivia, B.A. | Presenter
2:40 PM
- 3:00 PM
Convention Center - Mile High Ballroom 4DEF
Managing Patients After They Start Glucagon-like Peptide-1 Drug Treatment: Dosage, Side Effects, Response, and Discontinuation
Mary E. Rinella, MD, FAASLD | Presenter
3:00 PM
- 3:20 PM
Convention Center - Mile High Ballroom 4DEF
Building a Coalition of Community Partners and Stakeholders to Address Treatment for Metabolic Dysfunction–Associated Steatotic Liver Disease
Sharon H Jaycox, PhD | Presenter
